"Global market for In Vitro Diagnostics will reach $126.9bn by 2022" according to visiongain report

A new report by visiongain, a London-based business information provider, predicts that the global market for in vitro diagnostics will be worth $126.9bn by 2022. The market generated sales of $47.6bn in 2011 and includes all devices, reagents, instruments or systems used to perform diagnoses from biological assays, or more generally, in a controlled environment outside the living organism. The IVD sector is currently the largest sector in the global medical devices market.

Hemant Mistry, healthcare industry analyst, says: “Even with the advances made in modern-day medicine, a major contributing factor in the cause of death by diseases is delayed or incorrect clinical diagnoses. The IVD market continues to remain an essential and valuable segment of the healthcare industry and in recent years has witnessed rapid growth fuelled by technological advancements, improved diagnostic tools and treatment monitoring, faster response times and increased availability of over-the-counter (OTC) tests, which patients can perform in the comfort and convenience of their homes”.

Visiongain’s research also suggests that the world IVD market may benefit from globalisation, as there has been a growing focus from medical device companies, including those involved with the development of IVD devices, towards the BRIC (Brazil, Russia, India and China) nations, where in recent years, owing to the growth of their respective economies, there has been a significant number of government initiatives to further build on each country’s respective healthcare facilities and infrastructure as a result of their increasing healthcare budgets. For example, it has been predicted that healthcare investment in emerging nations such as China and India is expected to double in the next seven years.

Visiongain predicts that the total IVD market will show strong growth before the end of our forecast period, as many branded drugs will also have specific diagnostic tests associated with them, especially for determining the patients who can benefit most from the drugs and who can tolerate higher doses. The use of these tests will further add to the growing trend of personalised medicine. The drive to provide patients with diagnostic testing options that are more accurate, easy-to-use, safe and convenient will sustain growth in the IVD market during the forecast period of this report.

For sample pages and further information concerning the visiongain report In Vitro Diagnostics: World Market Outlook 2012-2022 please visit: http://www.visiongain.com/Report/845/In-Vitro-Diagnostics-World-Market-Outlook-2012-2022

For an executive summary of this report or to order it today please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on

Visiongain
BSG House
226-236 City Road
London EC1V 2QY
United Kingdom

This release was published on openPR.